Mouse Monoclonal Antibody Targeting Tetanus Toxin Heavy Chain Fragment C
Posted Jul 13 2009 5:00pm
Description of Invention: The FDA is pleased to announce as available for licensing a murine monoclonal antibody that specifically binds to Fragment C of tetanus toxin. Tetanus toxin is one of the most potent neurotoxins known. It is a complex molecule, composed of a linked heavy chain and light chain, each having different domains serving different functions. One domain of the heavy chain, known as "Fragment C," is known to bind the toxin to neurons. Fragment C is the focus of much research, including: analysis of the subtle differences between neuronal uptake of tetanus toxin and the related botulinum toxin, the design of compounds that block the uptake of tetanus toxin, and design of drugs that target the same cellular mechanism to enhance uptake.
Cell-based imaging agents
New drug development, including antitoxins
Advantages: Toxin specific-site antibodies
Development Status: Cell line (mouse-spleen hybridoma) established to produce antibodies.
Inventors: Marjorie A Shapiro (FDA) Sean P Fitzsimmons (FDA)
Patent Status: HHS, Reference No. E-061-2009/0
Research Materials -- patent protection is not being pursued for this technology
SP Fitzsimmons, KJ Clark, R Wilkerson, MA Shapiro. Inhibition of tetanus toxin fragment C binding to ganglioside G(T1b) by monoclonal antibodies recognizing different fragment C epitopes. Vaccine 2000 Aug 15;19(1):114-121. [ PubMed abs ]
Licensing Status: Available for non-exclusive Biological Materials Licensing.
Collaborative Research Opportunity: The FDA's Office of Biotechnology Products in the Center for Drug Evaluation and Research is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize antibodies directed against tetanus toxin. Please contact Alice Welch, Ph.D. at 301-827-0359 or Alice.Welch@fda.hhs.gov for more information.
Portfolios: Infectious Diseases Infectious Diseases - Research Materials
For Additional Information Please Contact: Susan Ano Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: email@example.com Phone: 301-435-5515 Fax: 301-402-0220